Avia Pharma acquires Libragel

Avia Pharma acquires Libragel

To further build on our ambition to improve health and well-being with a focus on women’s health, Avia Pharma have acquired Libragel and included it in our OTC portfolio. Libragel, a protective vaginal gel, was developed by a team of researchers at the Karolinska Institute in collaboration with some of Sweden’s most established midwives and sexologists.

“Libragel was originally developed for women who have been receiving cancer treatment, a group of women who often suffer from dry and sensitive epithelia. But every second woman in the ages 30-60 years suffers from dry and sensitive epithelia in the vagina from time to time so there is a great need for a pain relieving and soothing gel like Libragel”, says Marie Wikman, Business Director OTC at Avia Pharma.

We are happy to take the next steps for Libragel with the aim of a Nordic launch.